Raymond James & Associates Kiniksa Pharmaceuticals, Ltd. Transaction History

Raymond James & Associates

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 08, 2022	SELL	$10.39 - $15.15 $569,309 - $830,129	-54,794 Closed	0 $0
Q3 2021 Nov 02, 2021	SELL	$11.39 - $16.23 $50,389 - $71,801	-4,424 Reduced 7.47%	54,794 $624,000
Q2 2021 Aug 11, 2021	BUY	$13.22 - $19.09 $283,674 - $409,633	21,458 Added 56.83%	59,218 $825,000
Q1 2021 May 14, 2021	SELL	$16.68 - $23.97 $227,598 - $327,070	-13,645 Reduced 26.54%	37,760 $699,000
Q4 2020 Feb 12, 2021	BUY	$14.8 - $21.15 $760,794 - $1.09 Million	51,405 New	51,405 $908,000

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $690M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.